The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients.
 
Pedro C. Barata
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Caris Life Sciences; Clovis Oncology (Inst); Dendreon (Inst); Eisai; EMD Serono; Pfizer
Research Funding - Blue Earth Diagnostics (Inst)
 
Umang Swami
No Relationships to Disclose
 
Adam Kessel
No Relationships to Disclose
 
Ellen Jaeger
No Relationships to Disclose
 
Sergiusz Wesolowski
No Relationships to Disclose
 
Jonathan Chipman
No Relationships to Disclose
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Elisabeth I. Heath
Honoraria - Bayer; Dendreon; Sanofi; Seagen
Consulting or Advisory Role - Agensys; Bayer; Dendreon
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pharmacyclics (Inst); Plexxikon (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Agensys; Bayer; Sanofi
Other Relationship - Caris Centers of Excellence
 
Lakshminarayanan Nandagopal
Honoraria - AstraZeneca
 
Daniel A. Vaena
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Exelixis; Genomic Health; natera; Seagen
Research Funding - Aeglea Biotherapeutics (Inst); AstraZeneca (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Compugen (Inst); Compugen (Inst); incyte (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); OBI Pharma (Inst); Peloton Therapeutics (Inst); Seagen (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Caris Centers of Excellence; Genomic Health
 
Benjamin Louis Maughan
Consulting or Advisory Role - Astellas Medivation; Bayer; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Peleton; Tempus
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Roberto Nussenzveig
Consulting or Advisory Role - Tempus
 
Mark Yandell
No Relationships to Disclose
 
Manish Kohli
Honoraria - Advanced Accelerator Applications
Travel, Accommodations, Expenses - Celgene
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Foundation Medicine; Foundation One Inc; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Oliver A. Sartor
Consulting or Advisory Role - Bayer; Clovis Oncology; Sanofi
Research Funding - Merck